Pfizer is set to gain approximately £2.66 billion (around $3.56 billion) from selling and buyback of Haleon shares. Goldman Sachs International announced that Pfizer sold 640 million ordinary shares of Haleon at 380 pence per share, slightly below Haleon's latest closing price of 392.90 pence, reflecting a 3.3% discount.
Additionally, Haleon has agreed to repurchase around 60.5 million shares from Pfizer at the same price in an off-market deal, totaling approximately £230 million. As a result of these transactions, Pfizer's stake in Haleon will decrease from around 22.6% to roughly 15%.
